Maxcyte, Inc. (NASDAQ: MXCT)

MaxCyte is a leading commercial cell engineering company specializing in the development and commercialization of enabling platform technologies for next-generation cell therapeutics, including cell and gene therapies. Operating at the intersection of biopharmaceutical innovation and advanced cellular research, the company provides proprietary Flow Electroporation technology to facilitate the precise engineering of a wide variety of cells. This technology supports the discovery, development, and commercialization of cell-based therapies, addressing unmet medical needs across oncology, autoimmune diseases, and genetic disorders. MaxCyte’s platform is designed to enhance the efficiency, scalability, and reproducibility of cell engineering, positioning it as a critical enabler for biopharmaceutical companies and research institutions.

MaxCyte generates revenue through multiple streams, including sales of its ExPERT family of instruments, proprietary processing assemblies (PAs), and consumables such as electroporation buffers. The company also earns recurring revenue from annual instrument license fees under research, clinical, and Strategic Platform License (SPL) agreements. SPL agreements provide additional revenue potential through precommercial milestones and commercial sales-based payments tied to customer product success. This diversified model ensures steady cash flow while offering long-term upside as cell therapy programs advance through clinical development and commercialization. Customers span biopharmaceutical companies, academic institutions, and government research organizations, reflecting broad adoption across the life sciences sector.

The company operates through the following segments:

• Instrument Sales and Licensing: This segment encompasses the sale and licensing of MaxCyte’s ExPERT platform, which includes five instruments—DTx, ATx, STx, GTx, and VLx—designed for scalable cell engineering from research to commercial manufacturing. Instruments are sold or licensed for research or clinical use, with associated annual fees generating recurring revenue. The segment also includes sales of proprietary PAs and consumables, which are essential for instrument functionality and customer workflows.

• Strategic Platform Licenses (SPLs): This segment focuses on long-term partnerships with cell therapy developers through SPL agreements. These agreements provide customers with access to MaxCyte’s cGMP-compatible platform, regulatory support via FDA Master Files, and technical expertise in exchange for annual license fees, precommercial milestones, and commercial royalties. SPL agreements are a key driver of future revenue growth, with over $2 billion in potential milestone payments tied to active and future programs.

• Services and Assays: Following the acquisition of SeQure Dx in January 2025, this segment offers gene-editing risk assessment services, including assays like GUIDE-seq and ONE-seq. These services support cell and gene therapy developers in evaluating on-target and off-target editing outcomes, aiding regulatory submissions and internal decision-making. The integration of SeQure’s capabilities expands MaxCyte’s value proposition by addressing critical safety and efficacy concerns in cell therapy development.

MaxCyte holds a strong position within the cell engineering industry, driven by its proprietary Flow Electroporation technology and a robust intellectual property portfolio. The company competes with established players such as Lonza Group AG, Thermo Fisher Scientific, Miltenyi Biotec, and Bio-Rad Laboratories, as well as smaller firms developing non-viral delivery technologies. MaxCyte’s competitive advantages include its platform’s ability to deliver high transfection efficiency and cell viability across a broad range of cell types and scales, from research to commercial manufacturing. The ExPERT platform’s scalability, regulatory support via FDA Master Files, and recurring revenue model further differentiate it from competitors. Additionally, the company’s SPL agreements foster deep partnerships with leading cell therapy developers, enhancing its market presence and long-term growth potential.

MaxCyte’s customer base includes a diverse mix of large biopharmaceutical companies, biotechnology firms, and academic research institutions. The company serves a majority of the top 25 pharmaceutical companies by global revenue, alongside hundreds of smaller biotech firms and translational research centers. Notable customers include the U. S. National Institutes of Health (NIH) and cell therapy developers with FDA-approved products. The company’s technology has been validated in over 75 clinical trials, supporting therapies for hematological malignancies, solid tumors, and genetic disorders. This broad adoption underscores MaxCyte’s role as a critical enabler of next-generation cell therapies.